Find and Pitch Jounalists, Get Your Story Covered

Tags: Isomorphic Labs Eli Lilly

	Profile	Recent Articles on Subject
1	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Eli Lilly releases new data on weekly insulin - 9 days ago Lilly has more positive data on its weekly insulin - 14 days ago Eli Lilly’s anti-vanity ad campaign for Oscars - 7 months ago Novartis is building a new radioligand plant in China - 10 months ago
2	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Lilly lays down $1B to be ‘first in biology’ with obesity gene therapies - 11 days ago Will the real Ozempic please stand up? Lilly, Novo face uphill counterfeit battle - 3 months ago Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work? - 4 months ago
3	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Eli Lilly’s once-weekly insulin shows promise in phase 3 trials - 14 days ago
4	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Eli Lilly Moves Closer to Bringing Diabetes Patients a Once-Weekly Insulin Alternative - 14 days ago With Direct-to-Patient Zepbound, Eli Lilly Takes a Stand Against Compounders and PBMs - 15 days ago Eli Lilly Drug Reduces Risk of Diabetes Onset, Building Case for Broader Use of the Therapy - about 1 month ago Eli Lilly Shows Appetite for Oral Immunology Drugs, Swallowing Morphic in $3.2B Deal - 2 months ago Eli Lilly Alzheimer’s Drug Lands FDA Approval, Introducing Competition to Eisai’s Leqembi - 3 months ago Eli Lilly Puts $1B on the Line to Expand its Cancer Radiopharmaceuticals Prospects - 3 months ago Eli Lilly Pumps $5.3B More Into Site for Making Metabolic Meds Zepbound & Mounjaro - 4 months ago
5	Adam Spatacco Motley Fool Community for top investors. Investingcommunity	Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know. - 15 days ago Did Eli Lilly Just Get a Leg Up on Novo Nordisk? - 2 months ago This Is Massive News for Eli Lilly Investors - 3 months ago Move Over, Mounjaro. Eli Lilly Has Another Blockbuster in the Making - 5 months ago Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why - 7 months ago
6	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more - about 1 month ago STAT+: Pharmalittle: We’re reading about AbbVie spending on doctors, a new Lilly deal, and more - 2 months ago STAT+: Pharmalittle: We’re reading about Lilly Alzheimer’s drug adcomm, Amylyx ALS drug flop, and more - 7 months ago STAT+: Pharmalittle: We’re reading about a Lilly obesity-drug ad, a $35 cap on inhalers, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 9 months ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - 9 months ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - 11 months ago STAT+: Pharmalittle: FTC challenges ‘inaccurately or improperly’ listed patents; Elliott builds stake in BioMarin - 11 months ago STAT+: Pharmalittle: Eisai reports injectable version of Alzheimer’s drug as effective as IV; Pfizer says combo flu and Covid shot shows strong response - 11 months ago STAT+: Pharmalittle: China arrests an Astellas exec accused of spying; weight-loss drugs are being tested in children - 11 months ago STAT+: Lilly complains to the U.S. International Trade Commission about unapproved versions of Mounjaro - 11 months ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - 12 months ago STAT+: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro - 12 months ago
7	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Lilly’s Zepbound slashed risk of developing diabetes - about 1 month ago As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will move on without them - 2 months ago STAT+: Eli Lilly to acquire Morphic for $3.2 billion - 2 months ago Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound - 11 months ago STAT+: Our expensive obesity drugs are worth it, Novo Nordisk and Eli Lilly argue in raft of studies - 11 months ago
8	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Pharmalittle: We’re watching positive Zepbound cardiovascular data, a move to take 23andMe private, and more - about 2 months ago STAT+: In surprise move, FDA calls for advisory committee on Lilly’s Alzheimer’s drug - 7 months ago STAT+: In drug development, large pharma companies’ staying power provides them an edge, Lilly’s chief medical officer says - 11 months ago
9	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Pharmalittle: We’re watching more positive data for Ozempic, a Lilly factory expansion, and more - 4 months ago
10	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Compounded, Counterfeit Semaglutide Poses Severe Risk to Patients - 5 months ago

Journalists covering Eli Lilly